Cargando…

Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies

Chimeric antigen receptor T (CART) cell immunotherapy has been remarkably successful in treating certain relapsed/refractory hematological cancers. However, CART cell therapy is also associated with toxicities which present an obstacle to its wider adoption as a mainstay for cancer treatment. The pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siegler, Elizabeth L., Kenderian, Saad S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485001/ https://www.ncbi.nlm.nih.gov/pubmed/32983132 http://dx.doi.org/10.3389/fimmu.2020.01973

Ejemplares similares

Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy
por: Sterner, Robert C., et al.
Publicado: (2022)

Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment
por: Yan, Zhiling, et al.
Publicado: (2021)

Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma
por: Wang, Xue, et al.
Publicado: (2022)

Chimeric antigen receptor T-cell therapy for multiple myeloma
por: Wang, Zehua, et al.
Publicado: (2022)

Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy
por: Riegler, Lara L, et al.
Publicado: (2019)

Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome
por: Bhaskar, Shakthi T., et al.
Publicado: (2022)

Case Report: Local Cytokine Release Syndrome in an Acute Lymphoblastic Leukemia Patient After Treatment With Chimeric Antigen Receptor T-Cell Therapy: A Possible Model, Literature Review and Perspective
por: Luan, Chengxin, et al.
Publicado: (2021)

Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future
por: Li, Long, et al.
Publicado: (2020)

CART Cell Toxicities: New Insight into Mechanisms and Management
por: Zahid, Anas, et al.
Publicado: (2020)

Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges
por: Xiao, Bu-Fan, et al.
Publicado: (2021)

Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia
por: Schorr, Christopher, et al.
Publicado: (2022)

Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
por: Hu, Yongxian, et al.
Publicado: (2016)

Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy
por: Zhang, Lina, et al.
Publicado: (2021)

Focused evaluation of the roles of macrophages in chimeric antigen receptor (CAR) T cell therapy associated cytokine release syndrome
por: Guo, Hanfei, et al.
Publicado: (2022)

Could cytokine release syndrome induce acute myelofibrosis in CD19 chimeric antigen receptor T cells therapy?
por: Lai, Xun, et al.
Publicado: (2020)

Cytokine release syndrome complicated with rhabdomyolysis after chimeric antigen receptor T-cell therapy: A case report
por: Zhang, Lan, et al.
Publicado: (2022)

Chimeric Antigen Receptor T‐Cells: Successful Translation of the First Cell and Gene Therapy From Bench to Bedside
por: Rodriguez‐Cartagena, Luis G., et al.
Publicado: (2018)

Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy
por: Amidi, Yalda, et al.
Publicado: (2022)

Is Prophylaxis the Only Way Out for Cytokine Release Syndrome Associated With Chimeric Antigen T-cell Therapy?
por: Dave, Prashil, et al.
Publicado: (2021)

Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications
por: Mirzaei, Hamid R., et al.
Publicado: (2017)

A Novel Treatment for Ewing’s Sarcoma: Chimeric Antigen Receptor-T Cell Therapy
por: Lin, Zili, et al.
Publicado: (2021)

Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer
por: Kandra, Prameela, et al.
Publicado: (2022)

The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook
por: Zhang, Hao, et al.
Publicado: (2022)

B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy?
por: Zhang, Zheng, et al.
Publicado: (2023)

Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
por: Timmers, Marijke, et al.
Publicado: (2019)

Corrigendum: Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications
por: Mirzaei, Hamid R., et al.
Publicado: (2019)

Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma
por: García-Guerrero, Estefanía, et al.
Publicado: (2020)

Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies
por: Xiao, Xinyi, et al.
Publicado: (2022)

Investigation of the risk factors to predict cytokine release syndrome in relapsed or refractory B-cell acute lymphoblastic leukemia patients receiving IL-6 knocking down anti-CD19 chimeric antigen receptor T-cell therapy
por: Gong, Wen-Jie, et al.
Publicado: (2022)

Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy
por: Wang, Zhenguang, et al.
Publicado: (2018)

Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy
por: Ferreros, Puri, et al.
Publicado: (2022)

Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy
por: Hong, Ruimin, et al.
Publicado: (2020)

Clinical Characterization and Risk Factors Associated with Cytokine Release Syndrome Induced By COVID-19 and Chimeric Antigen Receptor T-Cell Therapy
por: Hong, Ruimin, et al.
Publicado: (2020)

The Chimeric Antigen Receptor Detection Toolkit
por: Hu, Yifei, et al.
Publicado: (2020)

Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies
por: Xiao, Xinyi, et al.
Publicado: (2021)

The Potential Role of the Intestinal Micromilieu and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy
por: Schubert, Maria-Luisa, et al.
Publicado: (2021)

Case report: Hashimoto’s thyroiditis after CD19 chimeric antigen receptor T-cell therapy
por: Chen, Panpan, et al.
Publicado: (2022)

Case Report: Chimeric Antigen Receptor T Cells Induced Late Severe Cytokine Release Syndrome
por: He, Jinping, et al.
Publicado: (2022)

Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma
por: Alkhateeb, Hassan B., et al.
Publicado: (2022)

Pleural cavity cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy: A case report
por: Ding, Lijuan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_l97pduff45gik3a1ushmf6tkqj